Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, Chen H, Berenson J.
Expert Rev Mol Diagn. 2018 Apr;18(4):319-329

Key Points +

The limited preclinical and ongoing clinical studies published to date evaluating BCMA-directed therapies have shown great promise. It has also been demonstrated that BCMA is solubilized and elevated in the blood of patients with:

  • Multiple myeloma (MM)
  • Waldenstrom’s macroglobulinemia (WM)
  • Chronic lymphocytic leukemia  (CLL)

BCMA is also responsible for the immune deficiency in MM. Reducing circulating levels may improve the efficacy of these treatments.